Xenobiotica最新文献_第7页

Selection of a Suitable Animal Model to Evaluate Secretion of Drugs in the Human Milk: A Systematic Approach 选择合适的动物模型来评估母乳中的药物分泌：一种系统方法

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-18 DOI: 10.1080/00498254.2024.2345283

Riya Nilkant, Chintha Kathiresan, Namrata Kumar, Steve Caritis, Imam H. Shaik, Raman Venkataramanan

引用次数: 0

EXPLORING PRECISION-CUT LIVER SLICES FOR COMPARATIVE XENOBIOTIC METABOLISM PROFILING IN SWINE AND CATTLE 探索精确切割肝脏切片用于猪和牛的异生物代谢谱对比分析

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-16 DOI: 10.1080/00498254.2024.2343905

Paula Ichinose, María Victoria Miró, Paula Viviani, Juan Manuel Herrera, Adrián Lifschitz, Guillermo Virkel

引用次数: 0

Academic foreign compound metabolism – ‘Quo vadis’? 学术界的外国化合物代谢--"Quo vadis"？

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-12 DOI: 10.1080/00498254.2024.2340740

S. C. Mitchell, R. H. Waring

引用次数: 0

Bioanalytical Approaches to Support the Development of Antibody-Oligonucleotide Conjugate (AOC) Therapeutic Proteins 支持抗体-寡核苷酸共轭物 (AOC) 治疗蛋白开发的生物分析方法

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-12 DOI: 10.1080/00498254.2024.2339983

Anthony Murphy, Ryan Hill, Michael Berna

引用次数: 0

Drug-drug interaction between danshensu and irbesartan and its potential mechanism 丹参素与厄贝沙坦的药物相互作用及其潜在机制

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-09 DOI: 10.1080/00498254.2024.2338183

Yuexia Li, Liheng Liu

引用次数: 0

MicroRNA-Mediated Krüppel-Like Factor 4 Upregulation Induces Alternatively Activated Macrophage-Associated Marker and Chemokine Transcription in 4,4’-Methylene Diphenyl Diisocyanate Exposed Macrophages 微RNA介导的克鲁珀尔样因子4上调诱导暴露于4,4'-亚甲基二苯基二异氰酸酯的巨噬细胞中替代活化的巨噬细胞相关标记物和趋化因子的转录

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-03 DOI: 10.1080/00498254.2024.2334329

Chen-Chung Lin, Brandon F. Law, Justin M. Hettick

引用次数: 0

Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson's drug FLZ after multi-dose in cynomolgus monkeys. 新型抗帕金森氏症药物 FLZ 在绒猴体内多次给药后的药代动力学和多峰现象分析

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-01 Epub Date: 2024-04-17 DOI: 10.1080/00498254.2024.2326475

Jiayu Li, Shuofeng Zhang, Rui Chen

{"title":"Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson's drug FLZ after multi-dose in cynomolgus monkeys.","authors":"Jiayu Li, Shuofeng Zhang, Rui Chen","doi":"10.1080/00498254.2024.2326475","DOIUrl":"10.1080/00498254.2024.2326475","url":null,"abstract":"The novel anti-Parkinson disease drug, FLZ, had a complicated drug absorption and metabolise process reported in single-dose studies. A multi-peak absorption peak phenomenon was found.This study focused on the multi-dose pharmacokinetics (PK) characteristics of FLZ, T1, and T2 in cynomolgus monkeys and raised discussion on its multi-peak absorption situation. Different doses of FLZ ranging from 75 to 300 mg/kg were administered orally to 16 cynomolgus monkeys. The whole treatment period lasted for 42 days with FLZ once a day.The primary metabolites of FLZ were Target1 (T1) and Target2 (T2), which had plasma exposure (calculated as AUC0-24, day 42) approximately 2 and 10 times higher than the parent drug. The proportion of plasma exposure increase was lower than the proportion of dose increase in FLZ, T1, and T2.Gender influenced its exposure (AUC0-24) with approximately 3-fold higher in males than females. There was no significant accumulation of T1 and T2. Enterohepatic Circulation (EHC) and gastrointestinal (GI) tract absorption may be involved in the mechanism of multi-peak characteristics.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"201-210"},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations. 探索第二代头孢菌素头孢克洛的药代动力学：对健康人群和患病人群的系统综述

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-01 Epub Date: 2024-04-02 DOI: 10.1080/00498254.2024.2333009

Tahir Saleem, Ammara Zamir, Muhammad Fawad Rasool, Imran Imran, Hamid Saeed, Faleh Alqahtani

{"title":"Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations.","authors":"Tahir Saleem, Ammara Zamir, Muhammad Fawad Rasool, Imran Imran, Hamid Saeed, Faleh Alqahtani","doi":"10.1080/00498254.2024.2333009","DOIUrl":"10.1080/00498254.2024.2333009","url":null,"abstract":"Cefaclor is a bactericidal antibiotic recommended for treating diverse types of infections. This review aims to comprehensively assess the pharmacokinetic (PK) data on cefaclor in humans.Google Scholar, PubMed, Cochrane Library, and EBSCO databases were systematically performed to identify all the relevant studies containing at least one reported PK parameter of cefaclor.Cefaclor shows the linear PK profile as the area under the plasma concentration-time curve from 0 to t (AUC0-t) and maximum plasma concentration (Cmax) increase in a dose-dependent manner. The AUC0-t of cefaclor in the rice diet was found to be higher than that of bread food, i.e. 19.9 ± 2.6 ug/ml.hr vs 15.4 ± 4 ug/ml.hr. The AUC in paediatrics during the fed state was significantly higher compared to that in adults. Patients with renal impairments showed a Cmax 2.2 times higher than that of normal subjects. A significant increase in Cmax was depicted among individuals following a vegetarian diet in comparison with the non-vegetarian diet. Moreover, cefaclor exhibits time-dependent killing above the minimum inhibitory concentration (MIC < 2 ug), favouring its use in treating infections caused by specific pathogens.This systematic review summarises all the reported PK parameters of cefaclor in healthy and diseased subjects in the literature. This data can help practitioners in adjusting cefaclor doses among different diseases and populations to avoid drug interactions and adverse effects.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"171-181"},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P₁ modulator ponesimod. S1P1 调节剂 ponesimod 的甘油侧链代谢降解过程中的可逆氧化/还原步骤。

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1080/00498254.2024.2319812

Alexander Treiber, Swen Seeland, Jérôme Segrestaa, Cyrille Lescop, Martin H Bolli

{"title":"Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P1 modulator ponesimod.","authors":"Alexander Treiber, Swen Seeland, Jérôme Segrestaa, Cyrille Lescop, Martin H Bolli","doi":"10.1080/00498254.2024.2319812","DOIUrl":"10.1080/00498254.2024.2319812","url":null,"abstract":"1. Ponesimod is a selective modulator of the sphingosine 1-phosphate receptor 1 (S1P1) approved for the treatment of active relapsing forms of multiple sclerosis. The chemical structure of ponesimod contains a glycerol side chain which is the major target of drug metabolism in humans.2. The two major metabolic pathways give the acids M12 (-OCH2CH(OH)COOH) and M13 (-OCH2COOH). While the former results from oxidation of the terminal alcohol, the mechanism yielding the chain-shortened acid M13 is less obvious. A detailed mechanistic study with human liver microsomes and hepatocytes using ponesimod, M12 and some of the suspected intermediates revealed an unexpectedly complex pattern of enzyme-mediated and chemical reactions.3. Metabolic pathways for both acids were not independent and several of the transformations were reversible, depending on reaction conditions. Formation of M13 occurred either via initial oxidation of the secondary alcohol, or as a downstream process starting from M12.4. The phenol metabolite M32 was produced as part of several pathways. Control experiments at various pH values and in the absence of metabolising enzymes support the conclusion that its formation resulted from chemical degradation rather than from metabolic processes.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"182-194"},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thank you to reviewers 感谢审稿人

IF 1.8 4区医学

Xenobiotica Pub Date : 2024-03-18 DOI: 10.1080/00498254.2024.2303194

引用次数: 0